Exelixis Reorganizes R&D And Cuts Its Workforce By 40 Percent
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech hopes to advance three late-stage compounds and others into development, but the overall tally will be reduced for the foreseeable future.